admin, Author at Invivoscribe

About admin

This author has not yet filled in any details.
So far admin has created 54 blog entries.

Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

admin2019-05-22T16:43:11+00:00August 22nd, 2018|Categories: Featured Publications, Publications|

Invivoscribe Announces a Regional “Center of Excellence” Reference Laboratory in Beirut to Offer Specialized Gene Panels

admin2019-07-04T21:09:48+00:00May 9th, 2018|Categories: Press Releases|Tags: Center of Excellence, Laboratory Network, LabPMM|

⟵ PRESS RELEASES PRESS RELEASE SAN DIEGO, [...]

Invivoscribe Submits Pre-Market Approval Application in Japan and Panel Track Supplement in the US to Screen Acute Myeloid Leukemia (AML) Patients for FLT3 Mutations

admin2019-07-04T21:11:12+00:00May 8th, 2018|Categories: Press Releases|Tags: Acute Myeloid Leukemia, AML, FLT3, FLT3 Mutations, Japan, Pre-Market Approval, US|

⟵ PRESS RELEASES PRESS RELEASE SAN DIEGO, [...]

Genetic Heterogeneity and Stratification of AML Samples with NPM1 Mutation Detected by the MyAML® NGS Test

admin2019-05-19T19:21:56+00:00November 16th, 2017|Categories: Posters|Tags: AML, Genetic Heterogeneity, MyAML, NGS Test, NPM1, Stratification|

DOWNLOAD POSTER ⟶

Validation of the LeukoStrat® CDx FLT3 Mutation Assay: Used to Detect both Internal Tandem Duplication (ITD) and Tyrosine Kinase Domain (TKD) Mutations and Response to Midostaurin in 1058 Patients with AML

admin2019-05-28T17:39:17+00:00November 16th, 2017|Categories: Posters|Tags: AML, Internal Tandem Duplication, ITD, LeukoStrat, LeukoStrat® CDx FLT3 Mutation Assay, Midostaurin, TKD, Tyrosine Kinase Domain|

DOWNLOAD POSTER ⟶

Multiple Highly Concordant Assays Facilitate Analyses of Clinical Samples at Different Scales and Sensitivities

admin2019-05-28T17:39:51+00:00November 16th, 2017|Categories: Posters|Tags: Assays, Clinical Samples, Multiple Highly Concordant Assays|

DOWNLOAD POSTER ⟶

We Are Invivoscribe

admin2019-05-28T17:43:18+00:00November 16th, 2017|Categories: Videos|Tags: Dr. Bradley Patay, Dr. Jeffrey E. Miller Ph.D., Global Distributors, Invivoscribe, Products, Services|

VIEW VIDEO ⟶

Clonality Detection Using Next-Generation Sequencing and Capillary Electrophoresis Methods in Suspect Lymphoproliferative Samples

admin2019-05-28T17:40:24+00:00November 16th, 2017|Categories: Posters|Tags: Capillary, Clonality, Lymphoproliferative, Next-Generation Sequencing, NGS|

DOWNLOAD POSTER ⟶

Detection of Clonal TRG and TRB Gene Rearrangements Using Next-Generation Sequencing

admin2019-05-28T17:40:54+00:00November 11th, 2017|Categories: Posters|Tags: Clonal TRB, Clonal TRG, Gene Rearrangements, Next-Generation Sequencing, NGS, TRB, TRG|

DOWNLOAD POSTER ⟶

Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)

admin2019-04-29T19:01:48+00:00August 9th, 2017|Categories: Publications|Tags: Mantle Cell Lymphoma, MCL, Minimal Residual Disease, MRD|

VIEW PUBLICATION ⟶

Load More Posts

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate
drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

March 21st, 2019
Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

August 25th, 2018
A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

August 22nd, 2018
Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

About admin

Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

Invivoscribe Announces a Regional “Center of Excellence” Reference Laboratory in Beirut to Offer Specialized Gene Panels

Invivoscribe Submits Pre-Market Approval Application in Japan and Panel Track Supplement in the US to Screen Acute Myeloid Leukemia (AML) Patients for FLT3 Mutations

Genetic Heterogeneity and Stratification of AML Samples with NPM1 Mutation Detected by the MyAML® NGS Test

Validation of the LeukoStrat® CDx FLT3 Mutation Assay: Used to Detect both Internal Tandem Duplication (ITD) and Tyrosine Kinase Domain (TKD) Mutations and Response to Midostaurin in 1058 Patients with AML

Multiple Highly Concordant Assays Facilitate Analyses of Clinical Samples at Different Scales and Sensitivities

We Are Invivoscribe

Clonality Detection Using Next-Generation Sequencing and Capillary Electrophoresis Methods in Suspect Lymphoproliferative Samples

Detection of Clonal TRG and TRB Gene Rearrangements Using Next-Generation Sequencing

Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Browse our comprehensive menu of product & testing services.

A proven strategy to acceleratedrug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

March 21st, 2019 Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

August 25th, 2018 A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

August 22nd, 2018 Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

About admin

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

A proven strategy to accelerate
drug approvals

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

March 21st, 2019
Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

August 25th, 2018
A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

August 22nd, 2018
Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL